Sunday, December 4, 2011 (All day)

Sunday, 4 December 2011

Clinigen Group, a global specialty pharmaceutical products and pharma services business, has been named the fastest-growing private company in the UK.

The Sunday Times Virgin Fast Track 100 league table, published today, ranks 100 UK-based firms according to their sales growth over the past three years. The Fast Track league tables have a strong track record of identifying promising and innovative entrepreneurial ventures that have gone on to become household names and successful international businesses. Companies listed in the past include ARM Holdings, Carphone Warehouse, Innocent and Jack Wills.

Commenting on Clinigen’s position at the top of the latest Fast Track 100 league table, group chief executive officer Peter George said: “This reflects robust organic growth in our original business lines, as well as the addition of Keats Healthcare in 2010. All of our businesses are closely aligned with Clinigen’s mission to get the right drug to the right patient at the right time, whether that’s in a clinical trial, a discontinued treatment, or for an individual patient need.”

In its short history, Clinigen Group has achieved 242% year-on-year growth, rising from an annualised £875,000 in 2008 to £35 million in the financial year ended June 2011.

Through its Healthcare Division, Clinigen acquires and in-licenses from the top 50 pharmaceutical companies mature or end-of-lifecycle drugs which have been targeted for discontinuation or withdrawal. Clinigen provides large companies with an attractive option for divesting non-core assets while ensuring an uninterrupted supply of products for patients and physicians. Clinigen also looks for opportunities to drive sales growth from the drugs it acquires.

“Our global reach gives us the edge in the specialty pharmaceuticals community,” commented Anton Jenkins, chief operating officer of Clinigen’s Healthcare Division. “Our presence and key networks in virtually all of the world’s major markets make Clinigen a partner of choice for big pharmaceutical companies wanting to divest mature assets. The alternative would likely be an onerous process, potentially requiring companies to sign multiple agreements with different partners in each territory.”

In March 2010, Clinigen acquired from AstraZeneca exclusive rights to sell the antiviral Foscavir in all global markets. Clinigen holds marketing authorisations to sell Foscavir as a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes in 16 markets, as well as in bone marrow transplantation in Japan. Clinigen is working with medicines regulatory agencies to secure licences to market Foscavir in additional markets, including the US in Q1 2012. Sales of Foscavir grew from £1.5 million last year to £9.7million in 2011 and are expected to reach £20.5 million in 2015.

“Clinigen Healthcare’s activities complement large pharmaceutical companies’ business need for effective portfolio management across the entire product lifecycle,” said Mr George. “Our work ensures that value is not lost from the pharmaceutical ecosystem and, most importantly, it provides treatment options for patients and physicians in areas of unmet medical need.”

“Managing clinical, pre-launch and end-of-lifecycle drugs on a global supply basis is a complex operation. By nature, it is a low volume, specialist supply process,” said Mr George. “But the growth that we have seen across our whole business provides a strong validation of the Clinigen business model. We expect to enjoy similar levels of success over the next few years as we apply Clinigen’s proven strategy to new product acquisitions and other new areas of business.”

About Clinigen

Clinigen Group is a specialty pharmaceutical and pharma services company formed by merger in 2010. Clinigen Healthcare, a company established in 2007 by executive chairman Andy Leaver, acquires or in-licenses mature or end-of-lifecycle products for development and commercialisation in hospitals. Clinigen Healthcare’s core therapeutic areas include oncology, leukaemia, haematology, transplantation, virology, pain management and critical care. The company also looks to acquire products that it can develop and commercialise in orphan indications.

Keats Healthcare (Clinigen CTS) became part of the Clinigen Group in 2010. Working in partnership with suppliers, pharmaceutical/biotech companies, and contract research and manufacturing organisations, Keats sources commercial medicinal products for exclusive use in customers’ clinical studies, including comparator trials. Keats has exclusive supply agreements with top 10 pharmaceutical companies.

Clinigen GAP offers tailored patient solutions, including named-patient, compassionate-use and early-access programmes. Clinigen GAP services help to ensure that markets are primed, fully supported and supplied while customers’ products go through the regulatory and launch process. They also support the withdrawal or discontinuation of pharma companies’ end-of-lifecycle products.

Clinigen Group is headquartered in Burton-on-Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan. For more information visit:

About Foscavir

Foscavir (foscarnet sodium) is licensed to treat cytomegalovirus (CMV) retinitis in HIV

patients and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised patients in Australia, Belgium, France, Germany, Hungary, Israel, Italy, Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Singapore, Spain, Switzerland and the UK. In July 2011, the Japanese Ministry of Health Labor and Welfare (MHLW) approved Foscavir for the treatment of CMV in hematopoietic stem cell transplant patients. For more information visit:


About The Sunday Times Virgin Fast Track 100

The Sunday Times Virgin Fast Track 100 league table ranks the UK’s 100 private companies with the fastest-growing sales over their latest three years. Fast Track 100 is published in The Sunday Times each December, with an awards event at Richard Branson's Oxfordshire home in May and follow-up regional dinners throughout the year. For more information visit:


Media contact:

Pete Chan at Tudor Reilly

Office: +44(0) 207 034 3208

Mobile: +44(0)7725 554 632


Back to News